4.7 Article

Anti-rejection drug treatment increases basal cell carcinoma burden in Ptch1+/- mice

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 124, Issue 1, Pages 263-267

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1111/j.0022-202X.2004.23573.x

Keywords

basal cell carcinoma; cyclosporine A; hedgehog; organ transplantation; patched

Categories

Funding

  1. NCI NIH HHS [CA81888] Funding Source: Medline
  2. NIAMS NIH HHS [AR050440] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [U19CA081888] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR050440] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The development of extensive and severe non-melanoma skin cancer is an extremely common complication of organ transplantation and is assumed to be caused by long-term treatment with anti-rejection drugs (ARD). Despite this florid clinical problem, ARD treatments have been reported to affect experimental murine skin carcinogenesis only weakly. We report here that treatment of cesium-137-irradiated Ptch1+/- mice with immunosuppressive doses of cyclosporine A plus prednisolone for 4-1/2 mo increased basal cell carcinoma burden by 2.5-fold. Thus, these mice provide a good model for study of the effects of long-term administration of ARD on at least one type of non-melanoma skin cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available